IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery
STUDY OVERVIEW
This study sponsored by Intuitive Surgical assesses the safety and effectiveness of IS-001 administered intravenously to enhance the visualization of the ureter during robotic-assisted surgery using the da Vinci® Surgical System and Firefly® imaging, aiming to address the common issue of ureter injury during pelvic and abdominal procedures.
STUDY GOALS
The study aims to evaluate the safety and efficacy of intravenous IS-001 injection in aiding intraoperative ureter delineation during robotic-assisted surgery with the da Vinci® Surgical System and Firefly® imaging.
LOCATION
El Paso, Texas: The Hospitals of Providence System
INCLUSION CRITERIA
Females aged 18 to 75 scheduled for robotic-assisted gynecological surgery using a da Vinci® system with Firefly® imaging.
Able and willing to give informed consent.
exclusion criteria
Pregnant or breastfeeding.
Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Currently enrolled in another drug or device study within the last 6 months.
Any condition that may interfere with data collection or poses safety concerns, as determined by the investigator.
Known or suspected allergy to indocyanine green (ICG).
Abnormal screening laboratory values: eGFR < 60 mL/min/1.73 m^2, AST/SGOT ≥ 2.5 × ULN, ALT/SGPT ≥ 2.5 × ULN.
For more information, visit ClinicalTrials.gov.